Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 212.6 SEK 2.21% Market Closed
Market Cap: 28.8B SEK
Have any thoughts about
Vitrolife AB?
Write Note
Section:
 

Relative Value

The Relative Value of one VITR stock under the Base Case scenario is 187.67 SEK. Compared to the current market price of 212.6 SEK, Vitrolife AB is Overvalued by 12%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VITR Relative Value
Base Case
187.67 SEK
Overvaluation 12%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8.1
P/S
P/S
Price to Sales
8.1
vs History
63
vs Industry
50
Median 3Y
8.8
Median 5Y
12.7
Industry
7.6
Forward
7.8
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
2
Median 3Y
63.3
Median 5Y
72.5
Industry
22.1
Forward
52.9
More Details
35.5
P/OCF
P/OCF
Price to OCF
35.5
vs History
69
vs Industry
5
Median 3Y
40.9
Median 5Y
50.8
Industry
21.9
More Details
55.2
P/FCFE
P/FCFE
Price to FCFE
55.2
vs History
49
vs Industry
3
Median 3Y
54.7
Median 5Y
61.3
Industry
23.4
More Details
2.2
P/B
P/B
Price to Book Value
2.2
vs History
53
vs Industry
39
Median 3Y
2
Median 5Y
2.6
Industry
2.5
More Details
8.4
EV/S
EV/S
Enterprise Value to Sales
8.4
vs History
65
vs Industry
40
Median 3Y
9.1
Median 5Y
12.3
Industry
7.5
Forward
8.1
More Details
14.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
14.4
vs History
68
vs Industry
29
Median 3Y
16
Median 5Y
19.5
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
6
Median 3Y
34
Median 5Y
44.5
Industry
4.2
Forward
23.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
4
Median 3Y
42.8
Median 5Y
46
Industry
4
Forward
37.3
More Details
36.7
EV/OCF
EV/OCF
Enterprise Value to OCF
36.7
vs History
68
vs Industry
4
Median 3Y
42.8
Median 5Y
49.7
Industry
5.9
More Details
45.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
45.4
vs History
63
vs Industry
4
Median 3Y
49.3
Median 5Y
60.9
Industry
3.9
More Details
1.9
EV/IC
EV/IC
Enterprise Value to IC
1.9
vs History
53
vs Industry
47
Median 3Y
1.7
Median 5Y
2.2
Industry
4.5
More Details

Multiples Across Competitors

VITR Competitors Multiples
Vitrolife AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Vitrolife AB
STO:VITR
28.8B SEK 8.1 -7.6 -8.4 -8.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.2B USD 5.6 61 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
142B USD 4.4 33.4 16.1 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
115B USD 4.1 910 10.1 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
101.6B USD 9.5 -211.2 20.8 21.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.5B USD 5.6 16.8 15.3 17
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.6 -109.5 -79.8
P/S Multiple
Revenue Growth P/S to Growth
SE
Vitrolife AB
STO:VITR
Average P/S: 3 457 240.7
8.1
24%
0.3
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
SE
Vitrolife AB
STO:VITR
Average P/E: 210.6
Negative Multiple: -7.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.4
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
910
77%
11.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -211.2
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Vitrolife AB
STO:VITR
Average EV/EBITDA: 16.2
Negative Multiple: -8.4
31%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
20.8
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Vitrolife AB
STO:VITR
Average EV/EBIT: 21.3
Negative Multiple: -8.4
44%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.8 N/A N/A

See Also

Summary
VITR intrinsic value, competitors valuation, and company profile.
DCF Valuation
VITR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VITR stock valuation using valuation multiples.
Wall Street Estimates
VITR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VITR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.